<DOC>
	<DOCNO>NCT01964950</DOCNO>
	<brief_summary>The purpose study examine safety efficacy long-term combination therapy alogliptin ( Nesina ) sulfonylurea patient type 2 diabetes mellitus respond inadequately treatment sulfonylurea addition diet therapy exercise therapy .</brief_summary>
	<brief_title>Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus : Combination Therapy With Sulfonylurea</brief_title>
	<detailed_description>This special drug use surveillance long-term use alogliptin 1-year ( 12-month ) observational period , design investigate safety efficacy long-term combination therapy alogliptin sulfonylurea patient type 2 diabetes mellitus routine clinical setting . Participants patient type 2 diabetes mellitus respond inadequately treatment sulfonylurea addition diet therapy exercise therapy . The planned sample size 1,000 . The usual adult dosage oral use 1 alogliptin tablet ( 25 mg ) daily .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Patients adequately respond follow treatment â€¢ Treatment sulfonylurea addition diet therapy exercise therapy Patients contraindicate Nesina 1 . Patients severe ketosis , diabetic coma precoma , type 1 diabetes mellitus ( patient require prompt adjustment hyperglycemia fluid infusion insulin , hence use Nesina appropriate . ) 2 . Patients severe infection , pre postoperative patient , patient serious traumatic injury ( blood glucose control insulin injection desirable patient , hence use Nesina appropriate . ) 3 . Patients history hypersensitivity ingredient Nesina</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>